Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial
- Registration Number
- NCT04979923
- Lead Sponsor
- Sheikh Zayed Medical College
- Brief Summary
The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 81
Inclusion Criteria
- Covid-19 positive
- Moderate to severe ARDS
Exclusion Criteria
- patients with COPD or taking bronchodilators and steroids for chronic respiratory illnesses
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Salbutamol group Lidocaine - Lidocaine group Lidocaine - Beclomethasone plus salbutamol Lidocaine -
- Primary Outcome Measures
Name Time Method Cough suppression within five minutes of initiation of treatment it will be assessed it will be assessed by using cough severity score
- Secondary Outcome Measures
Name Time Method correction of hypoxia immediately before and after intervention it will be assessed by PaO2
Trial Locations
- Locations (1)
Sheikh zayed medical college & hospital
🇵🇰Rahim Yar Khan, Punjab, Pakistan